Hereditary Cancer Surveillance Using Cell-free DNA Sequencing

Hereditary Cancer Surveillance Using Cell-free DNA Sequencing

This webinar is a recorded presentation of a live broadcast and includes a pre-test, the presentation, handout, and a post-test. Continuing education credit is available for the webinar.

This interactive live webinar is part 8 of the 8 part Utility of Cell-Free DNA in the Clinic Series.


This presentation will discuss findings from multiple different types of hereditary cancer syndromes utilizing a combination of mutational, fragmentomic, and epigenetic approaches to cell-free DNA analysis. It will also introduce data sharing and analytic strategies to increase the sensitivity and impact of these techniques.

Carriers of hereditary cancer syndromes are at heightened risk for malignancy and therefore undergo annual clinical screening for a host of cancers. As cancers are now well-known to shed cell-free DNA into the blood stream, the CHARM consortium (Cell-free DNA in Hereditary and High-risk Malignancies, was founded to assess whether regular genome and methylome profiling of blood plasma can detect the earliest cancers in this population. This presentation will examine this initiative.

Learning Objectives:
  • Identify some of the challenges with the collection, generation, and interpretation of liquid biopsy data in clinical studies
  • Compare different biological aspects of cell-free DNA and associated technologies to detect early cancer
  • Examine initiatives in hereditary cancer to assess the use of cell-free DNA sequencing technologies for cancer screening

    Trevor Pugh, PhD, FACMG
    Princess Margaret Cancer Centre
    Ontario Institute for Cancer Research
    Lynette Scholl, MD
    Harvard-Brigham and Women's Hospital
    Date Recorded: February 2, 2023
    Duration: 1 Hour
    Level of Instruction: Basic

    Supported by an educational grant from AstraZeneca and by educational funding provided by Amgen.  

    Continuing Education Credit Information

    Recording Date: February 2, 2023
    CME credit: 1.0
    CMLE credit: 1.0 
    Last day to claim credit: December 31, 2023

    Physicians (ACCME)           

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Association for Molecular Pathology.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation Statement – Amedco LLC designates this live to enduring activity for a maximum of 8.00 AMA PRA Category 1 CreditsTM (1.00 CE for each webinar). Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Medical Laboratory Education (CMLE)

    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for up to 8 CMLE credits. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

    Note: Join the AMP Family for discounted access to the most current educational resources!

    All sales are final. No refunds will be issued.

    No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation